Low-dose IL-2 as a therapeutic agent for tolerance induction

Immunotherapy

Volumn 3, Issue 11, 2011, Pages 1281-1284

  Malek, Thomas R ^a   Pugliese, Alberto ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

IL 2; T regulatory cells; tolerance; Type 1 diabetes

Indexed keywords

INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; STAT5 PROTEIN; TRANSCRIPTION FACTOR FOXP3;

ANTIGEN EXPRESSION; CELL MATURATION; CELLULAR IMMUNITY; DRUG MEGADOSE; GENETIC VARIABILITY; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; INSULIN DEPENDENT DIABETES MELLITUS; LOW DRUG DOSE; MYASTHENIA GRAVIS; NONHUMAN; OBSTRUCTIVE AIRWAY DISEASE; PRIORITY JOURNAL; REGULATOR GENE; REGULATORY T LYMPHOCYTE; REVIEW;

ANIMALS; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 1; HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY; INTERLEUKIN-2; MICE; MICE, INBRED C57BL; T-LYMPHOCYTES, REGULATORY;

EID: 80755189357     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.11.120     Document Type: Review

References (24)

1. Malek TR, Castro I. Interleukin 2 receptor signalling: at the interface between tolerance and immunity. Immunity 33, 153-165 (2010).
2. Lafreniere R, Rosenberg SA. Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma. J. Immunol. 135, 4273-4280 (1985). (Pubitemid 16250425)
3. Rosenberg SA, Lotze MT, Muul LM et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine activated killer cells and interleukin 2 or high dose interleukin 2 alone. N. Engl. J. Med. 316, 889-897 (1987). (Pubitemid 17041979)
4. Atkins MB. Interleukin 2: clinical applications. Semin. Oncol. 29, 12-17 (2002).
5. Abrams D, Levy Y, Losso MH et al. Interleukin 2 therapy in patients with HIV infection. N. Eng. J. Med. 361, 1548-1559 (2009).
6. Boyman O, Kovar M, Rubinstein MP, Surh CD, Sprent J. Selective stimulation of T cell subsets with antibody-cytokine immune complexes. Science 311, 1924-1927 (2006).
7. + CD25hi Foxp3+ regulatory T cells in cancer patients. Blood 107, 2409-2414 (2006). (Pubitemid 43345561)
8. Nishikawa H, Sakaguchi S. Regulatory T cells in tumor immunity. Int. J. Cancer 127, 759-767 (2010).
9. Grinberg-Bleyer Y, Baeyens A, You S et al. IL 2 reverses established Type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells. J. Exp. Med. 207, 1871-1878 (2010).
10. Tang Q, Adams JY, Penaranda C et al. Central role of defective interleukin 2 production in the triggering of islet autoimmune destruction. Immunity 28, 687-697 (2008).
11. Letourneau S, Van Leeuwen Em, Krieg C et al. IL 2/anti-IL 2 antibody complexes show strong biological activity by avoiding interaction with IL 2 receptor a subunit CD25. PNAS 107, 2171-2176 (2010).
12. Goudy KS, Johnson MC, Garland A et al. Inducible adeno-associated virus-mediated IL 2 gene therapy prevents autoimmune diabetes. J. Immunol. 186, 3779-3786 (2011).
13. Webster KE, Walters S, Kohler RE et al. In vivo expansion of T reg cells with IL 2-mAb complexes: induction of resistance to EAE and long-term acceptance of islet allografts without immunosuppression. J. Exp. Med. 206, 751-760 (2009).
14. Liu R, Zhou Q, La Cava A, Campagnolo DI, Van Kaer L, Shi FD. Expansion of regulatory T cells via IL 2/anti-IL 2 mAb complexes suppresses experimental myasthenia. Eur. J. Immunol. 40, 1577-1589 (2010).
15. Wilson MS, Pesce JT, Ramalingam TR, Thompson RW, Cheever A, Wynn TA. Suppression of murine allergic airway disease by IL 2:anti-IL 2 monoclonal antibody-induced regulatory T cells. J. Immunol. 181, 6942-6954 (2008).
16. Yu A, Zhu L, Altman NH, Malek TR. A low interleukin 2 receptor signaling threshold supports the development and homeostasis of T regulatory cells. Immunity 30, 204-217 (2009).
17. Phillips B, Trucco M, Giannoukakis N. Current state of Type 1 diabetes immunotherapy: incremental advances, huge leaps, or more of the same? Clin. Dev. Immunol. 2011, 432016 (2011).
18. Lowe CE, Cooper JD, Brusko T et al. Large-scale genetic fine mapping and genotype-phenotype associations implicate polymorphism in the IL2RA region in Type 1 diabetes. Nat. Genet. 39, 1074-1082 (2007). (Pubitemid 47340651)
19. Buckner JH. Mechanisms of impaired regulation by CD4(+)CD25(+)FOXP3(+) regulatory T cells in human autoimmune diseases. Nat. Rev. Immunol. 10(12), 849-859 (2010).
20. Kaye WA, Adri MN, Soeldner JS et al. Acquired defect in interleukin 2 production in patients with Type I diabetes mellitus. N. Engl. J. Med. 315, 920-924 (1986). (Pubitemid 16023678)
21. Zier KS, Leo MM, Spielman RS, Baker L. Decreased synthesis of interleukin 2 (IL 2) in insulin-dependent diabetes mellitus. Diabetes 33, 552-555 (1984). (Pubitemid 14113348)
22. + regulatory T cells of Type 1 diabetic subjects. Diabetes 59, 407-415 (2010).
23. Long SA. Rapamycin plus IL 2 combination therapy in subjects with T1D results in a sustained increase in IL 2 responsiveness and a transient decrease in C-peptide levels. Presented at: 71st Scientific Sessions American Diabetes Association Annual Meeting. San Diego, CA, USA, 24-28 June 2011.
24. Pugliese A. Insulin: a critical autoantigen and potential therapeutic agent in Type 1 diabetes. Exp. Rev. Clin. Immunol. 2, 419-431 (2006). (Pubitemid 44355573)